Skip to main content

COVID 19 Updates from RheumNow

Is MTX Safe in the Elderly? (12.1.2023)

Dr. Jack Cush reviews this past week's news and journal reports from RheumNow.com. Good news is that nearly 99% of adult rheumatology positions matched! But the challenge is that 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled in the 2024 NRMP match.

Sleep Apnea Smart Watches (10.13.2023)

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.

RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)

This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.

Respiratory Burden of RA

Over the last few decades, the availability of biologic and targeted synthetic DMARDs has revolutionized the treatment of RA, resulting in improved mortality and lower likelihood of joint deformities and disability.

Pizza and Rheumatoid Arthritis (8.11.2023)

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Patient Perspectives on Telemedicine Use During the Pandemic

Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients.

Hold the Methotrexate for One Week

In 2018, Park et al showed optimal responses to influenza vaccination in rheumatoid arthritis (RA) patients was best achieved by holding methotrexate (MTX) for 2 weeks following immunization, with improved humoral responses.

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

What is Colchicine Worth? (6.23.2023)

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

Allergic Drug-Induced Arthritis (5.19.2023)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

One in Ten is Bad! (5.12.2023)

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

  1. Does King Charles have Sausage Digits (dactylitis) or OA? https://t.co/mRis21OWKH

2022 EULAR Recommendations on Screening and Prophylaxis for Opportunistic Infections

Opportunistic and chronic infections may be rare and are often difficult to diagnose, especially in patients with autoimmune inflammatory rheumatic diseases (AIIRD), that may be immunocompromised. A EULAR task force has established recommendations for screening and prophylaxis against OI. 

Social

🔥 HOT OFF THE PRESS for #ACR23 Effectiveness of a fourth dose of #COVID19 mRNA #vaccine in patients with systemic autoimmune rheumatic diseases using DMARDs: an emulated target trial https://t.co/bvc75BP4aG @zach_wallace_md @jeffsparks https://t.co/CAlgjvUr9X
The Lancet Rheumatology @TheLancetRheum ( View Tweet )
3 weeks ago
COVAD2 data: ⬆️proportion of SLE pts from lmHDI countries were on CS(73% vs 59% p=0.0002), antimalarials(81% vs 68% p=0.0002) & IS(66% vs 53%p=0.0009) vs pts from hvhHDI countries Comorbids more in younger pts from lmHDI (prob from CS use) #ACR23 ABST2269 @RheumNow @rheumarhyme https://t.co/4CLGFYG1d0
sheila ( View Tweet )
3 weeks 1 day ago
Kevin. Winthrop knocks it down on WHO is immunocompromised among rheumatic disease pts at Innovation Theater ⁦@CCalabreseDO⁩ #ACR23 ⁦@alhkim⁩ ⁦@AdamJBrownMD⁩ ⁦@ELittlejohnDO⁩ https://t.co/4hFtQgvaIf
Leonard Calabrese @LCalabreseDO ( View Tweet )
3 weeks 2 days ago
Our collaborative study on nirmatrelvir-ritonavir (Paxlovid) virologic rebound is out in @AnnalsofIM @DrJLi @zach_wallace_md -Paxlovid: 21% with rebound vs. 2% in untreated (OR 10) https://t.co/RRDxerGdBy

Jeffrey Sparks MD MMSc @jeffsparks ( View Tweet )

3 weeks 2 days ago
Is rituximab still a problem with COVID - esp if our patients have been vaccinated pre-ritux? Antibody titres better when not getting regular ritux around boosters Maybe boosters 9mo (or so) gap after ritux helps immunogenicity @TroldborgAnne et al #ACR23 ABST2511 @RheumNow https://t.co/dE0uC6B9hx
David Liew @drdavidliew ( View Tweet )
3 weeks 2 days ago
A#2316 #ACR23 @RheumNow 91 SLE pts w COVID v 182 SLE wo COVID ifn 11 SLE/COVID: serious disease 1 death, 7 severe compl W/in 90d, 15% mild/mod SLE flare 2% severe SLE flare Flare rate 17.6% higher than no COVID ifn 5% p=0.001 High HV ifn (2% v 1%) dsDNA/C3 changes not signif diff https://t.co/dxGJNNWuFy
Eric Dein ( View Tweet )
3 weeks 2 days ago
Two-week interruption of MTX for IMIDs enhanced boost of antibody responses after COVID-19 vaccination, sustained at 12, 26 weeks. Consistent across ages, MTX doses, route, IMIDs, primary vaccination platform,COVID-19, Abhishek A Abst#1677 #ACR23 @RheumNow https://t.co/T0KdsGh6vg

Dr. Antoni Chan ( View Tweet )

3 weeks 3 days ago
VROOM 🏎️ study 2 wks interruption of MTX just after COVID vaccine: -Increase S1-RBD Ab response for 26 wks -Improves Neutralizing Ab titres (Wuhan Hu-1) -Leads to more flares wks 4 & 12 Greater effect when MTX dose>15mg @RheumNow #ACR23 ABST1677 https://t.co/SJmaRHtbRH
Aurelie Najm ( View Tweet )
3 weeks 3 days ago
Abishek et al. 2 week break from MTX enhances response to COVID-19 vaccination, mirroring what we saw for flu. Trade off is short term worsening of disease activity. Abstr#1677 #ACR23 @RheumNow https://t.co/gguRWER81x https://t.co/1hncvDTahH
Richard Conway ( View Tweet )
3 weeks 3 days ago
@Dr_K presenting long COVID data from FORWARD RA. These pts had some symtoms before COVID!- More comorbidites, depression patient reported scores, fibromyalgia but no different DMRD use. PHQ8 and wodepread paid were the most important PROMs @RheumNow #ACR23 https://t.co/JaWc4oDnaI
Bella Mehta @bella_mehta ( View Tweet )
3 weeks 3 days ago
×